A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
Clinical trial NCT05615636 · RECRUITING
Trial details
- NCT number
- NCT05615636
- Sponsor
- M.D. Anderson Cancer Center
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-04-28
- Primary completion
- 2027-08-19
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.